Paper28039265
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
Chung V and 7 others. Clin Cancer Res, 2017. Cited by 109 papers, by iCite.
Cite this record
ConductScience Library. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Papers, record 28039265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28039265
- Disease
- breast cancer1,032 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
- PubMed
Connected records8
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases8
- breast cancerOne of its trials lists the paper1,032 drugs, 4,781 trials
- prostate cancerOne of its trials lists the paper757 drugs, 2,173 trials
- ovarian cancerOne of its trials lists the paper567 drugs, 1,149 trials
- pancreatic adenocarcinomaOne of its trials lists the paper265 drugs, 498 trials
- thymomaOne of its trials lists the paper45 drugs, 41 trials
- chondrosarcomaOne of its trials lists the paper41 drugs, 28 trials
- testicular cancerOne of its trials lists the paper27 drugs, 12 trials
- fibrosarcomaOne of its trials lists the paper12 drugs, 9 trials
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bridged Bicyclo Compounds, Heterocyclic | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Neoplasms | Major topic |
| Piperazines | Major topic |
| Protein Phosphatase 2 | Major topic |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Staging |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01837667 | Phase I Study of LB-100 With Docetaxel in Solid Tumors | Results |
Source ClinicalTrials.gov
Cited by76
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42947971 | PP2A targeting: balancing anticancer potential and neurological risk. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42947971 | PubMed |
| 42882465 | Protein Tyrosine Phosphatases in Cancer: From Oncogenic Drivers to Therapeutic Targets. | Cells | 2026 | https://conductscience.org/library/papers/42882465 | PubMed |
| 42266180 | The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42266180 | PubMed |
| 42141450 | SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/42141450 | PubMed |
| 42065040 | Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells: Targeting RAS/RAF Signalling. | Oncol Res | 2026 | https://conductscience.org/library/papers/42065040 | PubMed |
| 42050705 | Translational control of AMPK activity in melanoma. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42050705 | PubMed |
| 41865130 | ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/41865130 | PubMed |
| 41736724 | A Small Molecule Inhibitor of Leucine Carboxyl Methyltransferase-1 Inhibits Cancer Cell Survival. | Front Drug Discov (Lausanne) | 2024 | https://conductscience.org/library/papers/41736724 | PubMed |
| 41502824 | On the history, synthesis, and medicinal use of cantharidin, LB-100, and their analogs. | RSC Med Chem | 2026 | https://conductscience.org/library/papers/41502824 | PubMed |
| 41354809 | Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives. | J Ovarian Res | 2025 | https://conductscience.org/library/papers/41354809 | PubMed |
| 41036607 | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41036607 | PubMed |
| 40354992 | A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC. | Cancer Lett | 2025 | https://conductscience.org/library/papers/40354992 | PubMed |
| 40349179 | PP2A Promotes the Symmetric Division of MUC1-Dominant Cancer Stem-Like Cells in Small Cell Lung Cancer. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40349179 | PubMed |
| 40006556 | LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006556 | PubMed |
| 39776803 | Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target. | Theranostics | 2025 | https://conductscience.org/library/papers/39776803 | PubMed |
| 39738384 | An AMBRA1, ULK1 and PP2A regulatory network regulates cytotoxic T cell differentiation via TFEB activation. | Sci Rep | 2024 | https://conductscience.org/library/papers/39738384 | PubMed |
| 39194238 | The cellular protein phosphatase 2A is a crucial host factor for Marburg virus transcription. | J Virol | 2024 | https://conductscience.org/library/papers/39194238 | PubMed |
| 38999976 | Role of Protein Phosphatases in Tumor Angiogenesis: Assessing PP1, PP2A, PP2B and PTPs Activity. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38999976 | PubMed |
| 38932511 | A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38932511 | PubMed |
| 38888850 | The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism. | Cell Oncol (Dordr) | 2024 | https://conductscience.org/library/papers/38888850 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PTPA | 5524 | PubTator's text mining | https://conductscience.org/library/genes/5524 |
Source NCBI Gene
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| DOCETAXEL | CHEMBL3545252 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3545252 | ChEMBL |
| LB-100 | CHEMBL4297300 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4297300 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28039265
GET https://conductscience.org/api/papers/v1/28039265/cited_by?page=2